1. |
Cuzzubbo S, Javeri F, Tissier M, et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer, 2017, 73: 1-8.
|
2. |
Spain L, Walls G, Julve M, et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol, 2017, 28(2): 377-385.
|
3. |
Touat M, Talmasov D, Ricard D, et al. Neurological toxicities associated with immune-checkpoint inhibitors. Curr Opin Neurol, 2017, 30(6): 659-668.
|
4. |
Psimaras D, Velasco R, Birzu C, et al. Immune checkpoint inhibitors-induced neuromuscular toxicity: from pathogenesis to treatment. J Peripher Nerv Syst, 2019, 24(Suppl 2): S74-S85.
|
5. |
Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med, 2016, 375(19): 1856-1867.
|
6. |
Pan PC, Haggiagi A. Neurologic immune-related adverse events associated with immune checkpoint inhibition. Curr Oncol Rep, 2019, 21(12): 108.
|
7. |
Kao JC, Liao B, Markovic SN, et al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol, 2017, 74(10): 1216-1222.
|
8. |
Dalakas MC. Neurological complications of immune checkpoint inhibitors: what happens when you “take the brakes off” the immune system. Ther Adv Neurol Disord, 2018, 11: 1-9.
|
9. |
Kao JC, Brickshawana A, Liewluck T. Neuromuscular complications of programmed cell death-1 (PD-1) inhibitors. Curr Neurol Neurosci Rep, 2018, 18(10): 63.
|
10. |
Chen X, Haggiagi A, Tzatha E, et al. Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy. Clin Neurophysiol, 2019, 130(8): 1440-1445.
|
11. |
Shirai T, Sano T, Kamijo F, et al. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol, 2016, 46(1): 86-88.
|
12. |
Nishijima TF, Shachar SS, Nyrop KA, et al. Safety and tolerability of PD-1/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis. Oncologist, 2017, 22(4): 470-479.
|
13. |
Luo W, Wang Z, Tian P, et al. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials. J Cancer Res Clin Oncol, 2018, 144(10): 1851-1859.
|
14. |
Psimaras D. Neuromuscular complications of immune checkpoint inhibitors. Presse Med, 2018, 47(11/12 Pt 2): e253-e259.
|
15. |
Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, version 1.2019. J Natl Compr Canc Netw, 2019, 17(3): 255-289.
|
16. |
Touat M, Maisonobe T, Knauss S, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology, 2018, 91(10): e985-e994.
|
17. |
Chen JH, Lee KY, Hu CJ, et al. Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: a case report and literature review. Medicine (Baltimore), 2017, 96(50): e9262.
|
18. |
Liewluck T, Kao JC, Mauermann ML. PD-1 inhibitor-associated myopathies: emerging immune-mediated myopathies. J Immunother, 2018, 41(4): 208-211.
|
19. |
Seki M, Uruha A, Ohnuki Y, et al. Inflammatory myopathy associated with PD-1 inhibitors. J Autoimmun, 2019, 100: 105-113.
|
20. |
Bilen MA, Subudhi SK, Gao J, et al. Acute rhabdomyolysis with severe polymyositis following ipilimumab nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. Immunother Cancer, 2016, 4(1): 36.
|
21. |
Anquetil C, Salem JE, Lebrun-Vignes B, et al. Immune checkpoint inhibitor-associated myositis: expanding the spectrum of cardiac complications of the immunotherapy revolution. Circulation, 2018, 138(7): 743-745.
|
22. |
Mammen AL, Rajan A, Pak K, et al. Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. Ann Rheum Dis, 2019, 78(1): 150-152.
|
23. |
Vermeulen L, Depuydt CE, Weckx P, et al. Myositis as a neuromuscular complication of immune checkpoint inhibitors. Acta Neurol Belg, 2020, 120(2): 355-364.
|
24. |
Day JA, Limaye V. Immune-mediated necrotising myopathy:a critical review of current concepts. Semin Arthritis Rheum, 2019, 49(3): 420-429.
|
25. |
Wang Y, Zhou S, Yang F, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol, 2019, 5(7): 1008-1019.
|
26. |
Suzuki S, Ishikawa N, Konoeda F, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology, 2017, 89(11): 1127-1134.
|
27. |
Hu JR, Florido R, Lipson EJ, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res, 2019, 115(5): 854-868.
|
28. |
Shah M, Tayar JH, Abdel-Wahab N, et al. Myositis as an adverse event of immune checkpoint blockade for cancer therapy. Semin Arthritis Rheum, 2019, 48(4): 736-740.
|